Abstract: The present disclosure provides a glycoengineered SARS-CoV-2 spike protein which is capable of eliciting an enhanced immune response relative to a native spike protein of SARS-CoV-2 and its variants. The glycoengineered spike protein exposes the glycosylation sites and at the same time preserves the tertiary structure of the spike protein. The present disclosure therefore provides improved immunogens, vaccines, and methods for better prevention and treatment of the emerging coronavirus infections.

Abstract: Disclosed herein are method and/or kit for rendering a diagnosis on whether a subject is suffering from peripheral neuropathy pain. The method comprises detecting the presence of advillin in a biological sample by forming an immune complex between advillin and a monoclonal antibody specifically binds thereto. Also disclosed herein is a method of treating a subject suffering from peripheral neuropathy pain.

Abstract: Provided herein are compounds of Formula (I). The compounds described herein are useful in treating a disease associated with the expression of endogenous embryonic/fetal globin (e.g., ? globin) in erythrocytes (e.g., treating ?-thalassemia and/or sickle cell disease through at least the induction of the globin gene expression in erythrocytes), and/or anemia (?-thalassemia and/or sickle cell anemia). The compounds described herein are useful in treating, delaying, and/or preventing the adverse effects of ?-thalassemia and/or sickle cell disease, inducing ? globin production, and/or inducing the expression of embryonic/fetal globin genes in a subject, cell, tissue, or biological sample. Also provided in the present disclosure are pharmaceutical compositions, kits, and methods of using the compounds for inducing ? globin production described herein and for treating any of the target diseases described herein.

Abstract: An isolated nucleic acid encoding a C-terminal fragment of paraspeckle component 1 (PSPC1) is disclosed. The C-terminal fragment of the PSPC1 comprises an extension of more than 10 but no greater than 131 amino acid residues with its C-terminal amino acid identical to the C-terminus of the PSPC1 sequence SEQ ID NO: 3 and exhibits a biological activity against tumor cells. The tumor cells are associated with either PSPC1 or protein tyrosine kinase 6 (PTK6), or both. The anti-tumor activity is at least one selected from the group consisting of: (a) suppressing tumor cell growth; (b) suppressing tumor cell progression; (c) suppressing tumor cell metastasis; (d) decreasing PSPC1 expression; and (e) decreasing oncogenic PTK6 expression in cytoplasm. Also disclosed is a peptide comprising a C-terminal fragment sequence of PSPC1. A reagent kit and method for predicting tumor progression, metastasis, and prognosis in a cancer patient are also disclosed.

Abstract: A transgenic rice plant containing in its genome a recombinant DNA construct that includes a first nucleic acid having a sequence of a first Golden 2-like transcription factor (GLK) gene operably linked to its natural promoter and 5? untranslated region (5?UTR), and a second nucleic acid having a sequence of a second GLK gene operably linked to its natural promoter and 5?UTR, the second GLK gene being distinct from the first GLK gene. The first GLK gene and the second GLK gene are both from a C4 plant and the transgenic rice plant exhibits a 65-106% increase in shoot biomass and a 50-95% increase in grain yield, as compared to an untransformed wild-type rice plant. Also provided is a method for producing the transgenic rice plant and a recombinant DNA construct that can be used in the method.

Abstract: Methods of preparing cell cultures (e.g. tumor spheroids), methods of evaluating a therapeutic agent for cancer, and methods of cancer treatment.

Abstract: The present disclosure relates to a chimeric influenza virus hemagglutinin (HA) polypeptide, comprising one or more stem domain sequence, each having at least 60% homology with a stem domain consensus sequence of H1 subtype HA (H1 HA) and/or H5 subtype HA (H5 HA), fused with one or more globular head domain sequence, each having at least 60% homology with a globular head domain consensus sequence of H1 subtype HA (H1 HA) or H5 subtype HA (H5 HA).

Abstract: The present invention provides novel pharmaceutical formulations comprising derivatives of NDGA, including M4N (tetra-0-methyl nordihydroguaiaretic acid) and temozolomide and their use in the inhibition and treatment of neoplastic diseases, including glioblastoma multiforme, lung and other cancers.

Abstract: The present disclosure relates to an antibody or antigen-binding fragment thereof that specifically binds to a spike protein of SARS-CoV-2. The present disclosure also relates to a pharmaceutical composition, a method for treating and/or preventing diseases and/or disorders caused by a coronavirus in a subject in need thereof, and a method for detecting a coronavirus in a sample.

Abstract: The present disclosure relates to mir-17˜92 as a candidate therapeutic or diagnostic target of motor neuron (MN) degeneration diseases. Expression of mir-17˜92 is sustained throughout adulthood in spinal MNs and specifically decreases before the onset of MN loss in SOD1G93A mice. Accordingly, mir-17˜92 can be used as a candidate therapeutic target for ALS.

Abstract: The present invention pertains to methods of coating antimicrobial peptides on the biomaterial and the biomaterial coated thereby. The coating solution described herein comprises one or more antimicrobial peptides (AMPs) dissolved in a buffer containing an anionic surfactant, wherein the AMPs are amphipathic and cationic.

Abstract: Compounds for use in prevention and/or treatment of pain are disclosed. The compounds are derived by conjugation of N6-(4-hydroxybenzyl)adenosine and analogous compounds with amino acids or peptides. In one embodiment of the invention, the compound is 5?-glycylcarbonyl-N6-(4-hydroxybenzyl)adenosine (I-a1). In another embodiment of the invention, the compound is 5?-deoxy-5?-(N?-glycylureido)-N6-(4-hydroxybenzyl)adenosine (I-d1). Also disclosed are methods of making and using the same.

Abstract: The present invention relates to a method for promoting growth of plants. Particularly, the method of the present invention features overexpression of a calcineurin B-like (CBL) interacting protein kinase15 (CIPK15) having an isoleucine (Ile) residue at position 48 (e.g. a CIPK15 from rice) in plants which can promote growth of the plants. The present invention also relates to a recombinant construct comprising a nucleic acid encoding the CIPK15 operably linked to a promoter. The present invention further relates to a transgenic plant overexpressing the CIPK15 exhibiting improved growth compared to a non-transgenic plant counterpart.

Abstract: Methods and computer-implemented methods are used to predict a risk of cardiovascular disease by using a machine learning mode to analyze a relationship between the occurrence of cardiovascular disease and the health data of patients.

Abstract: Provided herein is a method for treating neurodegenerative diseases, such as Alzheimer's disease (AD), by use of monoclonal antibody, which exhibits a binding affinity to Siglec-3 receptor. According to some embodiments of the present disclosure, the monoclonal antibody is capable of enhancing phagocytosis of neurotoxic peptides by immune cells thereby providing a neuroprotective effect to a subject in need thereof.

Abstract: Provided herein are compounds of Formula (I). The disclosure provides new compounds, compositions, and methods for treating, delaying, and/or preventing the adverse effects of proliferative diseases, such as cancers including, for example, lung cancer, breast cancer, ovarian cancer, prostate cancer, head cancer, neck cancer, head and neck cancer, or leukemia (e.g., cancer resistant to treatment by one or more microtubule-targeting agents (e.g., cancer resistant to multiple drugs associated with P-glycoprotein (P-gp) overexpression)). Provided are methods of inhibiting polymerization of a cancer cell microtubule in a subject in need thereof or a cell, tissue, or biological sample, binding ?-tubulin, inhibiting microtubule assembly and, inducing apoptosis in a cancer cell resistant to multiple drugs in a tissue, biological sample, or subject. Also provided in the present disclosure are pharmaceutical compositions, kits, and methods of using the compounds for treating any of the target diseases described herein.

Abstract: A method of generating an internally fixed lipid vesicle, comprising: providing a precursor lipid vesicle that contains an aqueous interior enclosed by a lipid membrane, wherein the lipid membrane of the precursor lipid vesicle is non-permeable to a crosslinker; permeabilizing the lipid membrane transiently to generate a permeable vesicle; contacting the permeable vesicle with an inactive activatable crosslinker, whereby the inactive activatable crosslinker enters the permeable vesicle; allowing the permeable vesicle to return to a non-permeable vesicle; removing any extravesicular crosslinker; and activating the inactive activatable crosslinker to allow crosslinking to occur inside the non-permeable vesicle, whereby an internally fixed lipid vesicle is generated.

Abstract: Disclosed herein is a novel monoclonal antibody exhibiting binding affinity to Siglec-3 receptor. According to the embodiment, the monoclonal antibody is capable of reversing HBV-induced immunosuppression. Accordingly, also disclosed herein are the uses thereof in the treatment and/or prophylaxis of hepatitis B virus (HBV) infection.

Abstract: The present invention generally relates to a method for treating a demyelinating condition, in particular, by administering a combination comprising therapeutically effective amounts of a Rho-associated protein kinase (ROCK) inhibitor, a cyclin-dependent kinase (CDK) inhibitor, and a cyclic adenosine monophosphate (cAMP) activator to a subject in need thereof.

Abstract: A method and apparatus for surface plasmon resonance imaging are provided for imaging the surface plasmon resonance signals caused by the interaction of biomolecules. In particular, the method and apparatus can image the slightly spectral change in a surface plasmon resonance mode by comparing the light intensities of two bands in the frequency domain of the surface plasmon.